Evaluation of The Effects and Side Effects of Topical Clobetasol 0.05% and Topical Anthralin Treatment in Alopecia Areata with Phototricogram

Aydan Yazıcı; Şükrü Balevi

Makale detayları

Evaluation of The Effects and Side Effects of Topical Clobetasol 0.05% and Topical Anthralin Treatment in Alopecia Areata with Phototricogram

Yazarlar:

Aydan Yazıcı | Şükrü Balevi

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.20 Issue 1, pp.13-18

Belge Tipi:

Makale

Yayın Tarihi:

3/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001343470

pISSN:

1303-6610

Anahtar kelimeler:

Özet:

 Objective: Alopecia areata AA is a chronic inflammatory disease characterized by non-scarring hair loss. In this study, we aimed to investigate the effects and side effects of topical anthralin and topical clobetasol propionate treatment in patients with AA using a phototrichogram. Material and methods: The study included 40 patients with AA who were randomly divided into two groups: topical anthralin n20 and clobetasol 17-propionate 0.05 n20. Phototrichogram values were assessed before and after treatment. Results: An evaluation of treatment response at the end of three months indicated inadequate response in 7 35, partial response in 8 40, and cosmetic response in 5 25 of the patients in the clobetasol 17-propionate 0.05 group as opposed to inadequate response in 4 20, partial response in 8 40, and cosmetic response in 8 40 of the patients in the local anthralin group. Although the cosmetic response rate was higher in the local anthralin group, there was no significant difference p0.470. The rate of patients unresponsive to treatment was lower in the topical anthralin group, while no significant difference was established p0.05. In patients whose treatment was not changed throughout the 6 months, cosmetic response was observed in 6 46.1 out of 13 65 patients who received local clobetasol 17-propionate 0.05 and in 10 62.5 out of 16 80 patients who received local anthralin and no significant difference was found between the groups p0.379. Statistically, treatment success was significantly higher in patients who did not respond to local clobetasol 17-propionate 0.05 treatment and were converted to anthralin treatment than those who underwent a treatment change p0.026. On the other hand, at the end of the 6 months, it was revealed that both drugs had no significant effect on the increase in the number of hair follicles per mm2 NH, hair density HD, anagen rate AR, and telogen rate TR values p0.148. Conclusion: Topical clobetasol 17 propionate 0.05 lotion and topical anthralin treatment is a safe and effective form of patchy AA treatment. When both drugs were compared, treatment success was statistically superior when switched to topical anthralin treatment in patients who did not respond to topical clobetasol 17 propionate 0.05 lotion. The results of our study and literature reviews indicate the necessity of studies with larger patient series in terms of the effectiveness of these two drugs.

 Objective: Alopecia areata AA is a chronic inflammatory disease characterized by non-scarring hair loss. In this study, we aimed to investigate the effects and side effects of topical anthralin and topical clobetasol propionate treatment in patients with AA using a phototrichogram. Material and methods: The study included 40 patients with AA who were randomly divided into two groups: topical anthralin n20 and clobetasol 17-propionate 0.05 n20. Phototrichogram values were assessed before and after treatment. Results: An evaluation of treatment response at the end of three months indicated inadequate response in 7 35, partial response in 8 40, and cosmetic response in 5 25 of the patients in the clobetasol 17-propionate 0.05 group as opposed to inadequate response in 4 20, partial response in 8 40, and cosmetic response in 8 40 of the patients in the local anthralin group. Although the cosmetic response rate was higher in the local anthralin group, there was no significant difference p0.470. The rate of patients unresponsive to treatment was lower in the topical anthralin group, while no significant difference was established p0.05. In patients whose treatment was not changed throughout the 6 months, cosmetic response was observed in 6 46.1 out of 13 65 patients who received local clobetasol 17-propionate 0.05 and in 10 62.5 out of 16 80 patients who received local anthralin and no significant difference was found between the groups p0.379. Statistically, treatment success was significantly higher in patients who did not respond to local clobetasol 17-propionate 0.05 treatment and were converted to anthralin treatment than those who underwent a treatment change p0.026. On the other hand, at the end of the 6 months, it was revealed that both drugs had no significant effect on the increase in the number of hair follicles per mm2 NH, hair density HD, anagen rate AR, and telogen rate TR values p0.148. Conclusion: Topical clobetasol 17 propionate 0.05 lotion and topical anthralin treatment is a safe and effective form of patchy AA treatment. When both drugs were compared, treatment success was statistically superior when switched to topical anthralin treatment in patients who did not respond to topical clobetasol 17 propionate 0.05 lotion. The results of our study and literature reviews indicate the necessity of studies with larger patient series in terms of the effectiveness of these two drugs.

 Objective: Alopecia areata AA is a chronic inflammatory disease characterized by non-scarring hair loss. In this study, we aimed to investigate the effects and side effects of topical anthralin and topical clobetasol propionate treatment in patients with AA using a phototrichogram. Material and methods: The study included 40 patients with AA who were randomly divided into two groups: topical anthralin n20 and clobetasol 17-propionate 0.05 n20. Phototrichogram values were assessed before and after treatment. Results: An evaluation of treatment response at the end of three months indicated inadequate response in 7 35, partial response in 8 40, and cosmetic response in 5 25 of the patients in the clobetasol 17-propionate 0.05 group as opposed to inadequate response in 4 20, partial response in 8 40, and cosmetic response in 8 40 of the patients in the local anthralin group. Although the cosmetic response rate was higher in the local anthralin group, there was no significant difference p0.470. The rate of patients unresponsive to treatment was lower in the topical anthralin group, while no significant difference was established p0.05. In patients whose treatment was not changed throughout the 6 months, cosmetic response was observed in 6 46.1 out of 13 65 patients who received local clobetasol 17-propionate 0.05 and in 10 62.5 out of 16 80 patients who received local anthralin and no significant difference was found between the groups p0.379. Statistically, treatment success was significantly higher in patients who did not respond to local clobetasol 17-propionate 0.05 treatment and were converted to anthralin treatment than those who underwent a treatment change p0.026. On the other hand, at the end of the 6 months, it was revealed that both drugs had no significant effect on the increase in the number of hair follicles per mm2 NH, hair density HD, anagen rate AR, and telogen rate TR values p0.148. Conclusion: Topical clobetasol 17 propionate 0.05 lotion and topical anthralin treatment is a safe and effective form of patchy AA treatment. When both drugs were compared, treatment success was statistically superior when switched to topical anthralin treatment in patients who did not respond to topical clobetasol 17 propionate 0.05 lotion. The results of our study and literature reviews indicate the necessity of studies with larger patient series in terms of the effectiveness of these two drugs.

 Amaç: Alopesia areata AA skarsız saç kaybıyla karakterize kronik inflamatuar bir hastalıktır. AAlı hastalara uygulanan topikal anthralin ve topikal klobetasol propiyonat tedavisinin etki ve yan etkilerini fototikogramla araştırmayı amaçladık. Gereç ve yöntemler: Alopesia areatalı 40 hasta çalışmaya alındı ve randomize olarak iki gruba ayrıldı. 20 hasta topikal  0.05 klobetasol 17 propionat losyon, 20 hasta topikal antralin tedavisi kullandı. Tedavi öncesi ve sonrası değerlendirme fototrikogram ile yapıldı. Bulgular: Üç ay sonunda tedavi yanıtı değerlendirildiğinde, klobetasol 17-propiyonat 0,05 uygulanan hastaların 7sinde 35 yetersiz yanıt, 8inde 40 kısmi yanıt, 5inde 25 kozmetik yanıt olduğu görüldü. Lokal antralin grubundaki hastaların 4ünde 20 yetersiz yanıt, 8inde 40 kısmi yanıt, 8inde 40 kozmetik yanıt gözlendi. Lokal antralin grubunda kozmetik yanıt oranı daha yüksek olmasına rağmen anlamlı fark yoktu p0,470. Topikal antralin grubunda tedaviye yanıt vermeyen hasta oranı daha düşüktü ancak anlamlı fark saptanmadı p0,05. Tedavisi 6 ay boyunca değişmeyen hastalarda lokal klobetasol 17-propiyonat 0,05 alan 13 65 hastanın 6sında 46,1 ve 10 62,5 hastada kozmetik yanıt gözlendi. Lokal antralin alan 16 80 hastada gruplar arasında anlamlı fark saptanmadı p0,379. Lokal klobetasol 17-propiyonat 0,05 tedavisine yanıt vermeyen ve antralin tedavisine geçen hastalarda tedavi başarısı, tedavi değişikliği yapılan diğer hastalara göre istatistiksel olarak anlamlı derecede yüksekti p0,026. Öte yandan 6 aylık süre sonunda her iki ilacın da mm2 başına saç kökü sayısı NH, saç yoğunluğu HD, anagen oranı AR ve telojen oranı TR artışına anlamlı bir etkisinin olmadığı ortaya çıktı p0,148. Sonuç: Topikal klobetasol 17 propiyonat 0,05 losyon ve topikal antralin tedavisi, yama tarzı AA tedavisinin güvenli ve etkili bir şeklidir. Her iki ilaç karşılaştırıldığında topikal klobetasol 17 propiyonat 0,05 losyona yanıt vermeyen hastalarda topikal antralin tedavisine geçildiğinde tedavi başarısının istatistiksel olarak üstün olduğu görüldü. Çalışmamızın sonuçları ve literatür taramaları bu iki ilacın etkinliği açısından daha geniş hasta serileri ile çalışmaların gerekliliğini göstermektedir.

Makale detayları

Evaluation of The Effects and Side Effects of Topical Clobetasol 0.05% and Topical Anthralin Treatment in Alopecia Areata with Phototricogram

Yazarlar:

Aydan Yazıcı | Şükrü Balevi

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.20 Issue 1, pp.13-18

Belge Tipi:

Makale

Yayın Tarihi:

3/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001343470

pISSN:

1303-6610

Alopecia areata

topical anthralin

phototricogram

topikal clobetazolalopesi areata

topikal anthralin

fototrikogram

topikal klobetazol

Sayı

Makale detayları

Yazarlar: Aydan Yazıcı | Şükrü Balevi

Yayıncı: Kahramanmaras Sutcu Imam University

Ana Başlıklar: Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi: Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.20 Issue 1, pp.13-18

Belge Tipi: Makale

Yayın Tarihi: 3/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001343470

pISSN: 1303-6610

Sayı

Yazarlar:

Aydan Yazıcı | Şükrü Balevi

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Hizmetleri ve Sistemleri (Diğer)

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.20 Issue 1, pp.13-18

Belge Tipi:

Makale

Yayın Tarihi:

3/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001343470

pISSN:

1303-6610